BioPharma Dive January 6, 2025
The European startup is one of several young companies developing oral macrocyclic peptides, which can slip into cells yet still interfere with protein interactions.
Dive Brief:
- Orbis Medicines, a European biotechnology startup, has raised 90 million euros, or about $93 million, in a Series A round announced Monday that will fund development of oral peptide drugs.
- Orbis is focused on “macrocycles,” a class of medicines that blends the strengths of small molecule and biologic drugs. The company aims to construct oral macrocycles that work against disease targets already validated by successful injectable medicines, but hasn’t specified which it will go after.
- Incubated by Novo Holdings, Orbis emerged from stealth last year with 26 million euros in seed funding. The...
Today's Sponsors
Today's Sponsor